pgdm1400
mAbexperimental
Clinical trial activity
10 trials · 18 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 23, 2017 (NCT03205917)
Timeline
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, passive
Human immunodeficiency virus immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06812494 | Phase 2 | Feb 1, 2025 | Department of Health and Human Services, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT06484335 | Phase 1 | Feb 1, 2025 | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Army |
| NCT06508749 | Phase 1/Phase 2 (Phase 2) | Oct 17, 2024 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05959707 | Phase 1 | Oct 14, 2023 | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), University of North Carolina at Chapel Hill |
| NCT05769569 | Phase 1 | Sep 1, 2023 | Chulalongkorn University, Henry M. Jackson Foundation for the Advancement of Military Medicine, Janssen Pharmaceutica NV, United States Army |
| NCT05184452 | Phase 1 | Nov 15, 2021 | Centre for the AIDS Programme of Research in South Africa, Department of Health and Human Services, Emory University, George Washington University, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT04983030 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2021 | Harvard University, Janssen Pharmaceutica NV, National Institute of Allergy and Infectious Diseases (NIAID), Orlando Immunology Center, University of Texas at Houston |
| NCT03928821 | Phase 1 | Jun 30, 2019 | Columbia University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03721510 | Phase 1/Phase 2 (Phase 2) | Dec 3, 2018 | Harvard University, International AIDS Vaccine Initiative, National Institute of Allergy and Infectious Diseases (NIAID), Orlando Immunology Center |
| NCT03205917 | Phase 1 | Oct 23, 2017 | Harvard University, International AIDS Vaccine Initiative, Ragon Institute of MGH, MIT and Harvard |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (18)
18 organizations
Page 1 / 1